Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naltrexone + nicotine is a combination therapy used for smoking cessation. Naltrexone is an opiate blocker that works by inhibiting the chemical signals within the brain that convey pleasure when people use drugs such as nicotine. When combined with nicotine replacement therapy (typically delivered via patches), this combination helps reduce cigarette cravings and lessens withdrawal discomfort. Research has shown this combination to be particularly effective for women, boosting smoking cessation rates by almost 50 percent when assessed after eight weeks of treatment. The combination also helps prevent the weight gain commonly associated with smoking cessation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naltrexone + nicotine.